摘要
目的探讨血小板与淋巴细胞比值(PLR)在表皮生长因子受体(EGFR)突变型非小细胞肺癌(NSCLC)靶向治疗疗效与预后评价中的价值。方法选取EGFR突变型NSCLC患者90例,于靶向治疗前计算PLR,以其中位数为截点分组,分为A组(低PLR组)和B组(高PLR组)。患者均予以EGFR-TKIs治疗。分析PLR与NSCLC临床病理特征的关系,比较两组间客观疗效、ORR、DCR、PFS与OS的差异。结果治疗前,PLR中位数为139,A组(低PLR组,PLR≤139)44例,B组(高PLR组,PLR> 139)46例。A组与B组在是否吸烟、肿瘤部位、组织分化、T分期、临床分期比较,差异有统计学意义(P <0.05)。A组PR、ORR、DCR率高于B组,PD率低于B组(P <0.05)。A组中位OS、中位PFS均长于B组(P=0.001)。结论 PLR在EG-FR突变型NSCLC靶向治疗疗效与预后评价中具有一定的参考价值,低PLR的EGFR突变型NSCLC患者经靶向治疗后具有更高的疗效和更长的存活期,是独立的预后评估因素。
Objective To explore the value of PLR in peripheral blood in the efficacy and prognosis of targeted therapy for NSCLC with EGFR-mutated. Methods Ninety patients with EGFR-mutant of NSCLC were selected,and the PLR was calculated before targeted therapy. The PLR median was used as a cut-off point for grouping, and they were assigned to group A(low PLR group)and group B(high PLR group). All patients were treated with EGFR-TKIs. Relationship between PLR and clinicopathological features was analyzed. Objective efficacy,ORR, DCR,PFS and OS between the two groups were compared. Results Before EGFR-TKIs therapy,median PLR was 139,and there were 44 patients in group A,and 46 in group B. There were statistical differences regarding smoking,tumor location,histological differentiation,T staging,and clinical staging between group A and B(P < 0.05). The rates of PR,ORR and DCR in group A were higher than those in group B,and the PD rate was lower than that in group B(P < 0.05). Log-rank test showed that median OS and median PFS in group A were longer than those in group B(P = 0.001). Conclusions PLR in peripheral blood has certain reference value for therapeutic effect and prognosis evaluation on NSCLC with EGFR-mutation. Low PLR of NSCLC patients with EGFR-mutation has higher efficacy and longer survival time after targeted therapy,and it is an independent and prognostic factor.
作者
江冠铭
刘克军
谭钦全
曾溢蕻
袁海姬
林顺欢
JIANG Guanming;LIU Kejun;TAN Qinquan;ZENG Yihong;YUAN Haiji;LIN Shunhuan(Department of Medical Oncology,Dongguan People′s Hospital,Dongguan 523029,China)
出处
《实用医学杂志》
CAS
北大核心
2019年第4期533-536,共4页
The Journal of Practical Medicine
基金
东莞市社会科技发展项目(编号:201750715001285)
关键词
非小细胞肺癌
表皮生长因子受体
血小板与淋巴细胞比值
靶向治疗
预后
non-small cell lung cancer
epidermal growth factor receptor
platelet-lymphocyte ratio
targeted therapy
prognosis